IBDEI2Q3 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45682,2)
 ;;=^5003751^F02.80
 ;;^UTILITY(U,$J,358.3,45683,0)
 ;;=G90.3^^200^2248^21
 ;;^UTILITY(U,$J,358.3,45683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45683,1,3,0)
 ;;=3^Multi-System Degeneration of the Autonomic Nervous System
 ;;^UTILITY(U,$J,358.3,45683,1,4,0)
 ;;=4^G90.3
 ;;^UTILITY(U,$J,358.3,45683,2)
 ;;=^5004162
 ;;^UTILITY(U,$J,358.3,45684,0)
 ;;=G91.2^^200^2248^22
 ;;^UTILITY(U,$J,358.3,45684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45684,1,3,0)
 ;;=3^NPH w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,45684,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,45684,2)
 ;;=^5004174^F02.81
 ;;^UTILITY(U,$J,358.3,45685,0)
 ;;=G91.2^^200^2248^23
 ;;^UTILITY(U,$J,358.3,45685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45685,1,3,0)
 ;;=3^NPH w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,45685,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,45685,2)
 ;;=^5004174^F02.80
 ;;^UTILITY(U,$J,358.3,45686,0)
 ;;=G30.8^^200^2248^5
 ;;^UTILITY(U,$J,358.3,45686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45686,1,3,0)
 ;;=3^Alzheimer's Diseases NEC
 ;;^UTILITY(U,$J,358.3,45686,1,4,0)
 ;;=4^G30.8
 ;;^UTILITY(U,$J,358.3,45686,2)
 ;;=^5003807
 ;;^UTILITY(U,$J,358.3,45687,0)
 ;;=G31.09^^200^2248^16
 ;;^UTILITY(U,$J,358.3,45687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45687,1,3,0)
 ;;=3^Frontotemporal Dementia NEC
 ;;^UTILITY(U,$J,358.3,45687,1,4,0)
 ;;=4^G31.09
 ;;^UTILITY(U,$J,358.3,45687,2)
 ;;=^329916
 ;;^UTILITY(U,$J,358.3,45688,0)
 ;;=G20.^^200^2248^24
 ;;^UTILITY(U,$J,358.3,45688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45688,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,45688,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,45688,2)
 ;;=^5003770^F02.81
 ;;^UTILITY(U,$J,358.3,45689,0)
 ;;=G20.^^200^2248^25
 ;;^UTILITY(U,$J,358.3,45689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45689,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,45689,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,45689,2)
 ;;=^5003770^F02.80
 ;;^UTILITY(U,$J,358.3,45690,0)
 ;;=G31.01^^200^2248^26
 ;;^UTILITY(U,$J,358.3,45690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45690,1,3,0)
 ;;=3^Pick's Disease
 ;;^UTILITY(U,$J,358.3,45690,1,4,0)
 ;;=4^G31.01
 ;;^UTILITY(U,$J,358.3,45690,2)
 ;;=^329915
 ;;^UTILITY(U,$J,358.3,45691,0)
 ;;=G23.1^^200^2248^28
 ;;^UTILITY(U,$J,358.3,45691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45691,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,45691,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,45691,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,45692,0)
 ;;=Z79.2^^200^2249^1
 ;;^UTILITY(U,$J,358.3,45692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45692,1,3,0)
 ;;=3^Antibiotics
 ;;^UTILITY(U,$J,358.3,45692,1,4,0)
 ;;=4^Z79.2
 ;;^UTILITY(U,$J,358.3,45692,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,45693,0)
 ;;=Z79.01^^200^2249^2
 ;;^UTILITY(U,$J,358.3,45693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45693,1,3,0)
 ;;=3^Anticoagulants
 ;;^UTILITY(U,$J,358.3,45693,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,45693,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,45694,0)
 ;;=Z79.02^^200^2249^3
 ;;^UTILITY(U,$J,358.3,45694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45694,1,3,0)
 ;;=3^Antiplatelets/Antithrombotics
 ;;^UTILITY(U,$J,358.3,45694,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,45694,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,45695,0)
 ;;=Z79.82^^200^2249^4
 ;;^UTILITY(U,$J,358.3,45695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45695,1,3,0)
 ;;=3^Aspirin
